Though the decision to adjust insulin doses at initiation is clearly influenced by specific patient characteristics such as level of glycemic control and current frequency of hypoglycemia, inherent antihyperglycemic features of SGLT2 therapy in patients with T1DM requires further analysis. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.